معرفی
John Blenis, PhD, is the Anna-Maria and Stephen Kellen Professor in Cancer Research and Professor of Pharmacology at Weill Cornell Medical College. His research focuses on biochemical mechanisms integrating extracellular signals, intracellular pathways, and metabolic processes to regulate cellular bioenergetics, mRNA metabolism, and protein synthesis. The lab pioneered studies on Ras/ERK/RSK, PI3K/Akt, and mTOR signaling, identifying cancer biomarkers and drug targets. Current work includes investigating mTOR-driven metabolic reprogramming, drug resistance mechanisms, and combination therapies for cancer.
Education: PhD (1983, Michigan State University), BS (1977, University of California, Berkeley).
Research Interests: mTOR signaling, metabolic regulation, kinase inhibitors, tumor microenvironment, propionate metabolism in cancer, and aging-related metabolic diseases. The lab employs high-throughput screens, CRISPR-based approaches, and metabolomics to uncover therapeutic targets.
Publications highlight mTOR's role in mRNA splicing, nutrient sensing, and oncogene addiction. Key findings include FABP5-mTORC1 fatty acid sensing and methylmalonic acid's role in metastasis.
Grants: Active NIH/NCI and DoD funding for projects targeting STING in cancer, BRCA1/2-deficient tumors, and folate/vitamin C combinations. Collaborates with industry via Elikia INC.
Labs/Teams: Leads a multidisciplinary team at Weill Cornell, collaborating with computational biologists and clinical researchers to translate findings into therapies.
